Brief: Amneal Launches Mesalamine And Receives U.S. FDA Approval For Lenalidomide
19/02/2025 15:06
Feb 19 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O :
* AMNEAL LAUNCHES MESALAMINE AND RECEIVES U.S. FDA APPROVAL
FOR
LENALIDOMIDE
Source text: ID:nBw2tmz5Fa
Further company coverage: AMRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amneal Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-3M Company, Constellation Energy, Metropolitan Bank Holding
US FDA is working with manufacturers to boost estrogen patch supply amid access concerns (updated)
U.S. RESEARCH ROUNDUP- Intuit, MongoDB, Zscaler
U.S. STOCKS ON THE MOVE-Mastercard, Yum, Equinix
Amneal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary